Welcome to our dedicated page for Traws Pharma SEC filings (Ticker: TRAW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking a clinical-stage biotech such as Traws Pharma means wading through pages of trial data, R&D footnotes, and milestone contingencies. Investors looking for pipeline updates, cash-runway signals, or dilution risk often get lost before reaching the relevant tables. That’s why Stock Titan gathers every Traws Pharma SEC filing in one place and converts jargon into plain language. From “Traws Pharma SEC filings explained simply” to pinpointing how Tivoxavir Marboxil trials affect revenue assumptions, our platform starts with the questions analysts actually ask.
The latest Traws Pharma annual report 10-K simplified by our AI highlights phase progression timelines, partnering agreements, and detailed R&D spend, while each Traws Pharma quarterly earnings report 10-Q filing is paired with instant variance analysis. Real-time alerts flag Traws Pharma Form 4 insider transactions in real-time so you can see executive stock movements minutes after they post. Need more depth? Our engine answers “understanding Traws Pharma SEC documents with AI” by offering side-by-side comparisons, sentiment heat maps, and drill-downs into non-cash charges.
Whether you want “Traws Pharma insider trading Form 4 transactions” before a data read-out, “Traws Pharma proxy statement executive compensation” to evaluate incentive alignment, or “Traws Pharma 8-K material events explained” after an unexpected clinical update, Stock Titan has you covered. Each document comes with concise, AI-powered summaries and hyperlinks to underlying tables, turning hours of manual review into minutes of actionable insight. Use our dashboard for Traws Pharma earnings report filing analysis, monitor Traws Pharma executive stock transactions Form 4 in real-time, and stay ahead of every disclosure that can move the share price.
Form 8-K highlights
On 30 June 2025, Traws Pharma, Inc. (Nasdaq: TRAW) furnished a Form 8-K to disclose two information items under Regulation FD. Item 7.01 notes that the company has adopted a new corporate presentation, filed as Exhibit 99.1 and simultaneously posted on its website. Item 8.01 attaches a press release (Exhibit 99.2) announcing that Traws has submitted multiple regulatory filings for candidates in its antiviral pipeline.
The company explicitly states that the furnished material is not deemed “filed” under Section 18 of the Exchange Act and will not be automatically incorporated into other SEC filings. No earnings figures, balance-sheet data, or transactional details accompany the disclosure. A boiler-plate forward-looking statement reminds investors that clinical, regulatory, and operational risks could cause actual outcomes to differ from expectations.
In essence, the 8-K signals incremental pipeline progress and provides investors with updated slide-deck messaging, but the absence of program-level details or quantitative milestones limits immediate valuation impact. The filing therefore serves primarily as a transparency gesture ahead of future catalysts rather than a material change to the investment thesis.
Traws Pharma (NASDAQ:TRAW) filed a routine Form 4 disclosing that director Clarke Trafford was granted 23,000 stock options on 06/19/2025. The options carry a $1.65 exercise price, vest 100 % after one year (06/19/2026) and expire on 06/19/2035. Following the grant, the reporting person now beneficially owns 23,000 derivative securities directly. No shares of common stock were bought or sold, and there are no indications of 10b5-1 trading plans or additional transactions in this filing.
Traws Pharma (NASDAQ:TRAW) filed a routine Form 4 reporting an insider equity grant. Director Jack E. Stover received 23,000 non-qualified stock options on 06/19/2025 at an exercise price of $1.65 per share. The options vest 100 % on the first anniversary of the grant date and expire on 06/19/2035. No open-market purchases or sales of common stock were disclosed, and the grant carries no immediate cash value to the director. Following the transaction, Stover beneficially owns 23,000 derivative securities, all held directly.
Traws Pharma (NASDAQ:TRAW) filed a routine Form 4 reporting that director Mary Teresa Shoemaker received 23,000 stock options on 06/19/2025 at an exercise price of $1.65 per share. The options vest 100% on the first anniversary of the grant date and expire on 06/19/2035. No shares were sold and no other material changes were disclosed.
Traws Pharma (TRAW) filed a routine Form 4 reporting that director Werner Cautreels received 23,000 stock options on 06/19/2025 at an exercise price of $1.65. The options vest 100% on the first anniversary of the grant date and expire on 06/19/2035. No common shares were bought or sold, and beneficial ownership remains unchanged apart from the new option grant.
FAQ
What is the current stock price of Traws Pharma (TRAW)?
What is the market cap of Traws Pharma (TRAW)?
What is Traws Pharma's core focus?
What is Tivoxavir Marboxil?
How does Traws Pharma approach drug discovery?
What clinical evidence supports their therapy programs?
Which therapeutic areas does Traws Pharma target?
How is Traws Pharma positioned within its competitive landscape?
